Dasiglucagon

Drug Profile

Dasiglucagon

Alternative Names: ZP 4207; ZP-GA-1

Latest Information Update: 26 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Zealand Pharma
  • Developer Beta Bionics; Boston University; Zealand Pharma
  • Class Antihypoglycaemics; Peptides
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperinsulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hypoglycaemia
  • Phase II Type 1 diabetes mellitus
  • Phase I Hyperinsulinaemia

Most Recent Events

  • 03 Jul 2017 Phase-III clinical trials in Hypoglycaemia (Treatment-experienced) in Canada, USA (SC) (EduraCT2017-000062-30)
  • 03 Jul 2017 Phase-III clinical trials in Hypoglycaemia (Treatment-experienced) in Germany (SC) (EduraCT2017-000062-30)
  • 03 Jul 2017 Positive adverse events data from a phase II trial in Hypoglycaemia released by Zealand Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top